Benjamin Harris Kaffenberger MD

Clinical Trials

• An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Start of enrollment: 2017 May 04

  Completed

  Phase 2

• The Ohio State University Dermatology Biorepository Start of enrollment: 2017 Apr 19

  Recruiting

• Effect of Teledermatology on Length of Hospital Admission, Length of Stay, 30 Day Readmission Rate, and Antibiotic Use in Patients Presenting With Cellulitis vs Pseudocellulitis in an Academic ED Setting Start of enrollment: 2016 Jan 01

  Completed

  Not Applicable

• The Effect of Dermatology and Teledermatology Consultations on Length of Hospital Admission, 30 Day Readmission Rate, and Antibiotic Use in Patients Presenting With Cellulitis vs Pseudocellulitis in an Academic Inpatient Setting Start of enrollment: 2016 Jan 01

  Completed

  Not Applicable

• The Effect of Histopathologic Analysis and Tissue Cultures on Inpatient Management of Cellulitis and Pseudocellulitis Start of enrollment: 2018 May 25

  COMPLETED

• A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Start of enrollment: 2021 Jul 12

  ACTIVE_NOT_RECRUITING

  PHASE2

• A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients Start of enrollment: 2019 Dec 09

  Active, not recruiting

  Phase 2

• Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum Start of enrollment: 2019 May 16

  Completed

  Phase 2

• An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Start of enrollment: 2014 Dec 01

  Terminated

  Phase 3

• A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Start of enrollment: 2014 Jan 31

  COMPLETED

  PHASE2

• An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Start of enrollment: 2014 Nov 01

  Terminated

  Phase 3

• Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) Start of enrollment: 2016 Oct 20

  COMPLETED

  PHASE2

• A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus Start of enrollment: 2017 Aug 31

  Completed

  Phase 2

• A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD) Start of enrollment: 2018 May 01

  COMPLETED

  PHASE3

• A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash Start of enrollment: 2021 May 04

  Terminated

  Phase 2

• A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica Start of enrollment: 2021 Apr 12

  Terminated

  Phase 2

• Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT) Start of enrollment: 2021 Jan 11

  Completed

  Phase 2

• A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC Start of enrollment: 2018 Dec 21

  RECRUITING

• Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne Start of enrollment: 2022 Mar 30

  RECRUITING

  PHASE4

• The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW) Start of enrollment: 2022 Mar 31

  COMPLETED

  PHASE2

  Roles: Principal Investigator

• Role of Intermittent Fasting in Psoriasis and Psoriatic Arthritis Start of enrollment: 2022 Jul 21

  Recruiting

  Not Applicable

  Roles: Principal Investigator

• Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum Start of enrollment: 2024 May 28

  RECRUITING

  NA

  Roles: Contact, Principal Investigator

• Join now to see all